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We report on the efficacy of selected endochin-like quinolones (ELQs) againstN. caninum
tachyzoites grown in human foreskin fibroblasts (HFF), and in a pregnant BALB/c
mouse model. Fourteen ELQs were screened against transgenic N. caninum tachyzoites
expressing β-galactosidase (Nc-βgal). Drugs were added concomitantly to infection and
the values for 50% proliferation inhibition (IC50) were determined after 3 days. Three
compounds exhibited IC50 values below 0.1 nM, 3 ELQs had IC50s between 0.1 and
1 nM, for 7 compounds values between 1 and 10 nM were noted, and one compound
had an IC50 of 22.4 nM. Two compounds, namely ELQ-316 and its prodrug ELQ-334
with IC50s of 0.66 and 3.33 nM, respectively, were previously shown to display promising
activities against experimental toxoplasmosis and babesiosis caused by Babesia microti
in mice, andwere thus further studied. They were assessed in long-term treatment assays
by exposure of infected HFF to ELQs at 0.5µM concentration, starting 3 h after infection
and lasting for up to 17 days followed by release of drug pressure. Results showed that
the compounds substantially delayed parasite proliferation, but did not exert parasiticidal
activities. TEM of drug treated parasites detected distinct alterations within the parasite
mitochondria, but not in other parasite organelles. Assessment of safety of ELQ-334
in the pregnant mouse model showed that the compound did not interfere in fertility
or pregnancy outcome. In N. caninum infected pregnant mice treated with ELQ-334 at
10 mg/kg/day for 5 days, neonatal mortality (within 2 days post partum) was found in
7 of 44 pups (15.9%), but no postnatal mortality was noted, and vertical transmission
was reduced by 49% compared to the placebo group, which exhibited 100% vertical
transmission, neonatal mortality in 15 of 34 pups (44%), and postnatal mortality for 18
of the residual 19 pups during the 4 weeks follow-up. These findings encourage more
research on the use of ELQs for therapeutic options against N. caninum infection.
Keywords: Neospora, Toxoplasma, endochin-like quinolones, mitochondrion, cytochromeb, electron microscopy,
vertical transmission, mouse model
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INTRODUCTION
Neospora caninum is an obligate intracellular coccidian parasite,
which is closely related to Toxoplasma gondii, and which until
1988 had been misdiagnosed as such (1). While the overall
shape, morphology and the fact that a large panel of animals
can be infected with N. caninum are features that it shares
with Toxoplasma, there are also some clearly distinct biological
characteristics that distinguish the two species. For instance,
canids such as dogs, dingoes, gray wolves, and coyotes are
known to act as definitive hosts for N. caninum (2–5), while
for Toxoplasma this role is taken over exclusively by felids.
N. caninum can infect a variety of intermediate hosts, including
economically important farm and food animals (6), but there
is no evidence that neosporosis could be zoonotic (1). This
is in stark contrast to Toxoplasma, which besides being an
economically important pathogen, also infects up to one third
of the human population, and can cause serious disease in
immunodeficient persons and/or upon primary infection during
pregnancy with serious consequences for the fetus (7).
Economically, N. caninum is most relevant in cattle, in
that it can cause repeated abortions, stillbirths and birth of
weak calves. This happens either upon primary infection
during pregnancy (exogenous transplacental transmission), or
through recrudescence in chronically infected dams caused
by immunomodulation during pregnancy (endogenous
transplacental transmission) (8, 9). In spite of considerable
investments, there is currently no commercially available vaccine
on the market (10). In the past, drug treatment has not been
envisaged as an interesting approach to combat neosporosis, and
due to the need of repeated treatments and the potential residues
that could remain in meat and milk products from animals
destined for consumption, drugs were regarded as economically
non-viable. However, the inherent difficulties in generating an
efficient vaccine for limiting the effects of neosporosis, most
notably in cattle, has sparked the interest for potential treatment
options.
An increasing number of compounds, repurposed from older
drugs, have been shown to exhibit a potential for drug treatment
of animals infected with N. caninum [reviewed in Hemphill
et al. (11)]. Many of these repurposed drugs and their more
recently synthesized analogs were developed for the treatment
of malaria, caused by the apicomplexan parasites Plasmodium
falciparum. These compounds have been greatly improved in
terms of high efficacy and specificity, low cytotoxicity, and
favorable pharmacokinetic properties, and drug repurposing has
demonstrated interesting activities not only against Plasmodium,
but also other protozoan parasites and also helminths (12, 13).
One of the most interesting compounds is endochin which
was proven to have a potent action against liver and erythrocytic
stages of an avian malaria model. Similar to other quinolones
such as atovaquone and buparvaquone, endochin inhibits the
cytochrome bc1 complex of the mitochondrial electron transport
chain of Plasmodium (14). Cytochrome bc1 facilitates the transfer
of electrons from ubiquinol to cytochrome c and contains both
oxidative (Qo) and reductive (Qi) catalytic sites. The anti-
malarial drug atovaquone is a classical Qo site inhibitor (15).
More recently, novel endochin analogs with a diphenylether side
chain at the third position, and various substitutions at position
5, 6, or 7 of the quinolone ring were synthesized. These include
ELQ-300 and ELQ-316, which confer Qi site inhibition (16, 17)
and ELQ-400 (18), which is an unusual inhibitor as it targets
both Qo and Qi sites of cytochrome bc1 of S. cerevisiae and
potentially other organisms (19). Structure-activity relationship
studies performed by Stickles et al. (18) and McConnell et al.
(20) showed that differential binding to either the Qo or Qi site
in P. falciparum and T. gondii cytochrome bc1 is dependent on
subtle changes in the structure of ELQs mediated by various
substitutions at different positions of the quinolone ring.
Due to poor aqueous solubility and high crystallinity, ELQ
analogs exhibit only limited oral absorption (21). To solve this
problem, prodrugs for the compounds with good efficacy in
vitro were created, which contain a carbonate ester pro-moiety
that disrupts crystallinity and increases oral bioavailability.
The prodrug is metabolized after administration and releases
the active compound, thus leading to increased exposure and
therefore improved efficacy (21, 22). One of the ELQs with
excellent efficacy against T. gondii is ELQ-316, a Qi site inhibitor
(23), exhibiting in vitro IC50 values below 1 nM, and in vivo
affecting not only tachyzoites, but also tissue cysts (16). ELQ-
316 and its prodrug ELQ-334 also exhibited excellent activities in
treating Babesia microti infections in immunodeficient mice (24).
In this study, we assessed the in vitro activities of 14 distinct
ELQ analogs against a transgenic N. caninum strain expressing
beta-galactosidase. We then focused on ELQ-316 and its prodrug
ELQ-334 and studied the effects of these compounds in terms of
parasiticidal vs. parasitostatic activity, ultrastructural alterations,
and assessed the safety and in vivo efficacy of ELQ-334 in the
pregnant neosporosis mouse model.
MATERIALS AND METHODS
Tissue Culture Media, Biochemicals, and
Compounds
If not stated otherwise, cell culture media were purchased from
Gibco-BRL (Zurich, Switzerland) and biochemical reagents were
obtained from Sigma (St. Louis, MO, USA). Kits for molecular
biology were purchased from Qiagen (Hilden, Germany). The
endochin-like quinolones (ELQs) were synthesized as previously
described (20), identified by proton nuclear magnetic resonance
(1H NMR), and determined to be >95% pure by reversed-phase
high-performance liquid chromatography (HPLC). For in vitro
studies, the compounds were stored as 20, 10mM, or 100µM
stock solution in dimethyl sulfoxide (DMSO) at −20◦C. For
in vivo experiments, ELQ-334 was suspended in corn oil and
administered to the mice by oral gavage.
Cell Culture and Parasites
Human foreskin fibroblasts (HFF), Vero cells andMarc cells were
cultured andmaintained as described earlier (25, 26). Tachyzoites
of the N. caninum isolate Nc-Spain7, and transgenic N. caninum
strain containing a beta-galactosidase reporter strain (Nc-βgal,
with Nc-1 background) were cultured either in Vero cells, Marc
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cells or HFF, and were maintained and prepared for infections as
described before (25–27).
Cytotoxicity Assessments
The toxicity of ELQs against host cells was assessed as previously
described (28, 29). Briefly, HFF were grown to confluence in
96 well-plates. After removal of the medium by aspiration, cells
received 200 µl fresh medium containing either 2, 1, 0.5, 0.25,
0.125, 0.062, and 0.031µM of each ELQ, respectively. Non-
treated HFF and DMSO controls were included. Plates were kept
in an incubator at 37◦C and 5% CO2 for 3 days. Subsequently,
medium was discarded from the well-plates by aspiration, and
cells were washed once with PBS. The resazurin stock solution
was diluted 1:200 in PBS, and 200 µl were added into each
well. Plates were read at λ excitation 530 nm and λ emission
590 nM at the EnSpire R© multimode plate reader. Fluorescence
was measured different timepoints. Relative fluorescence units
were calculated from timepoints with linear increase.
In vitro Proliferation Measurements
Employing Nc-βgal Tachyzoites
Primary screening of the 14 ELQs assessed in this study (see
Table 1) was performed using the transgenic Nc-βgal strain
cultured in HFF as described earlier (28, 29). HFF monolayers
were cultured in 96-well plates, and infected with 103 Nc-βgal
tachyzoites per well in the presence of ELQs (stock solutions of
100µM in DMSO), prepared in serial dilutions in the following
concentrations: 200, 20, 2, 0.2, 0.02, 0.002, and 0.0002 nM in
medium, respectively. The stock solution, as well as, the medium
were heated up to 37◦C prior to use. After 3 days of culture
in the presence of the drugs, wells were washed once with
200 µl PBS, and 90 µl PBS containing 0.05% Triton X-100
solution was added to each well. After addition of 10 µl of
5mM chlorophenolred-β-D-galactopyranoside dissolved in PBS,
the absorption shift was measured at a 570 nM wavelength at
various timepoints on a VersaMax multiplate reader (Bucher
Biotec, Basel, Switzerland). IC50s were calculated after the logit-
log transformation of relative growth and subsequent regression
analysis by use of the corresponding software tool contained in
the Excel software package (Microsoft, Seattle, WA).
In vitro Proliferation Measurements
Employing Nc-Spain7 Tachyzoites
Employing Quantitative Real-Time PCR
HFF were grown in 6-well plates until a confluent monolayer
was formed. Just prior to infection, ELQ-316 and ELQ-334
were added at concentrations of 200, 20, 2, 0.2, 0.02, 0.002,
and 0.0002 nM. Controls received the corresponding amounts of
DMSO. HFF were then infected with 3 × 105 freshly purified
tachyzoites of N. caninum Nc-Spain7. After 4 days, cells were
collected with a cell scraper, centrifuged, and washed in PBS.
DNA purification was performed employing the DNeasy blood
and tissue kit (Qiagen, Basel, Switzerland) according to the
standard protocol suitable for animal cells. N. caninum parasite
load was determined by real-time PCR as previously described
(30). IC50s were calculated as described above.
Long-Term Treatment Assays
To assess the effects of extended treatments with ELQs, 5 ×
105 HFF were grown to confluence in T25 flasks and were then
infected with 1 × 106 Nc-Spain7 tachyzoites for 3 h, washed
2 times with HBSS (Hanks balanced salt solution), and were
then exposed to 500 nM ELQ-316 or ELQ-334 for periods of
either 3, 6, 9, 12, 14, or 17 days, with medium changes and
addition of fresh medium containing the compounds every 3
days. Following treatments, cultures were washed twice with
HBSS and were further maintained in medium devoid of drugs.
Regrowth of parasites was monitored on a daily basis by light
microscopy, until plaques and proliferating parasites were visible,
for a maximum period of 3 weeks after drug removal.
Transmission Electron Microscopy (TEM)
TEM was carried out essentially as described (25). Briefly, 5 ×
105 HFF were grown in T25 flask for 96 h, and were infected
with 1 × 106 N. caninum Nc-Spain7 tachyzoites. After 4 h,
the medium and non-invaded parasites were removed, flasks
were washed twice with medium, and infected cultures were
maintained at 37◦C/5% CO2, for 48 h. Subsequently, 1µM of
ELQ-316 and ELQ-334 were added, and after 6, 12, 24, 48, or
72 h, the medium was discarded and the flasks were washed
twice with 0.1M Na-Cacodylate buffer (pH 7.3), and fixed in 2%
glutaraldehyde in 0.1MNa-Cacodylate buffer for 10min at room
temperature. Then, infected monolayers were carefully removed
using a cell scraper, transferred into an Eppendorf tube and
fixation was continued for 2 h. The specimens were post-fixed
in 2% OsO4 in cacodylate buffer washed in water, followed by
immersion in Uranylless solution (Electron Microscopy Science,
Hatfield PA, USA) for 20min. Following stepwise dehydration in
a graded series of ethanol, specimens were embedded in Epon-
812 resin, with three changes of epoxy resin every 10–12 h.
Following polymerization at 60◦C, ultrathin sections were cut
using an ultramicrotome (Reichert and Jung, Vienna, Austria),
and were placed onto 200 mesh nickel grids (Plano GmbH,
Marburg, Germany). Following staining with Uranylless and lead
citrate, specimens were viewed on a CM12 transmission electron
microscope operating at 80 kV.
Immunofluorescence Labeling of ELQ
Treated Tachyzoites
HFF monolayers were grown to 50% confluency on glass
coverslips in 24-well plates and infected with 3 × 104 Nc-
Spain7 tachyzoites. After 3 h, specimens were exposed to 1µM
ELQ-316 and ELQ-334 and the culture was continued for
a maximal duration of 14 days. At different timepoints, the
coverslips were washed once in PBS, followed by fixation and
preparation for immunofluorescence as previously described
(25, 31, 32). The following primary antibodies were used: (i)
anti-IMC1, a rabbit polyclonal antibody directed against the
inner membrane complex (IMC1), kindly provided by Prof.
Dominique Soldati-Favre, University of Geneva, diluted 1:500;
(ii) anti-SAG1, a mouse monoclonal antibody directed against
the major immunodominant tachyzoite surface antigen1 (33)
diluted 1:1000. Primary antibodies were applied for 20min at
room temperature in PBS with 0.3% bovine serum albumin
(BSA). After four washes in PBS, the corresponding secondary
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TABLE 1 | IC50 values of ELQ compounds as determined by N. caninum and T. gondii transgenic strains expressing β-galactosidase.
Code MW Structure LogP NcIC50
(nM)
TgIC50
(nM)a
Endochin 287.4 3.35 0.75 0.07
ELQ-432 321.8 3.91 22.45 43
ELQ-433 305.4 3.51 4.67 3.8
ELQ-127 257 3.5 2.45 2.8
ELQ-136 275.4 3.63 0.02 0.13
ELQ-121 293.3 3.79 0.08 0.006
ELQ-436 313.5 5.15 1.04 0.68
ELQ-434 377.9 5.58 3.81 11
ELQ-437 349.5 5.46 0.09 0.003
(Continued)
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TABLE 1 | Continued
Code MW Structure LogP NcIC50
(nM)
TgIC50
(nM)a
ELQ-435 361.5 5.18 2.01 0.24
ELQ-300 475.8 5.66 0.33 25
ELQ-316 459.4 5.26 0.66 0.35
ELQ-271 411 5.22 2.75 5.6
ELQ-334 531.4 8.1 3.33 ND
ELQ-437 349.5 5.46 0.09 0.003
a Indicates results reported in McConnell et al. (20); ND, not done.
antibody conjugates (anti-mouse fluorescein isothiocyanate
[FITC] or anti-rabbit Texas Red [Sigma-Aldrich]) were applied
at a dilution of 1:300 in PBS with 0.3% BSA. After four washes
in PBS, specimens were incubated for 3min in 4′,6-diamidino-
2-phenylindole (DAPI) diluted 1:300 in PBS with 0.3% BSA,
washed again for 4 times in PBS, and mounted in Vectashield
mounting medium (Vector Laboratories, Burlingame, CA, USA).
All specimens were viewed on a Nikon Eclipse E800 digital
confocal fluorescence microscope. Processing of images was
performed using the OpenLab 5.5.2 software (Improvision,
PerkinElmer, Waltham, MA, USA).
ETHICS STATEMENT
All protocols involving animals were approved by the Animal
Welfare Committee of the Canton of Bern under the license
BE115/14. Animals were handled in strict accordance with
practices made to minimize suffering. Female and male BALB/c
mice, 8 weeks of age were purchased from a commercial breeder
(Charles River, Sulzberg, Germany), and were maintained
in a common room under controlled temperature and a
14 h/10 h light cycle, with food accessible ad libitum. All
procedures were carried according to the guidelines set up
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by the animal welfare legislation of the Swiss Veterinary
Office.
Assessment of Potential Effects of
ELQ-334 on Pregnancy Outcome in
Non-infected BalB/c Mice
Twelve BALB/c female and 6 male mice, 8 weeks of age
(purchased from Charles River, Germany) were used. two groups
of six mice were prepared (2 females per cage, 3 cages per group),
one ELQ-334 treatment group, and one placebo-treatment
group. Females were oestrus-synchronized by the Whitten effect
and were mated for three nights by housing 1 male with 2 females
(27, 34, 35). After 3 days, males were removed from the cages.
Treatments with ELQ-334 were performed from day 9–13 post-
mating, calculated from the first day of mating. Prior to the
treatment, ELQ-334 was suspended in corn oil, at 10 mg/kg body
weight in 100 µl inoculation volume administered by gavage.
The placebo group received the equal volume of corn oil only.
The weight of each mouse was measured several times during the
pregnancy period to determine the number of pregnant animals
and to detect possible abortions (which would cause rapid weight
loss). On day 18 post-mating, pregnant females were separated
into individual cages, where they gave birth on days 20–22 post-
mating. Live and stillborn pups were counted, and dead pups
were removed. Data on the number of female mice that became
pregnant, litter size (number of delivered pups per dam), stillborn
mice (number of full-term dead pups from birth until day 2 p.p.);
post-natal mortality (number of dead pups from day 3 p.p to
the end of the experiment) and clinical signs of treated mice
were recorded. Dams and live pups were monitored at least until
2 weeks after birth to rule out possible adverse effects due to
treatments. At the end of the experiment, pups were euthanized
by decapitation. Adult mice were euthanized in a euthanasia
chamber using isoflurane and CO2.
Assessment of ELQ-334 Treatment
Efficacy in Non-pregnant and Pregnant
BALB/c Mice Experimentally Infected With
Nc-Spain7
Twenty-eight BALB/c female and 14 male mice, 8 weeks of age
and provided by Charles River, were maintained as described
above. Two groups of 14 mice were prepared (2 females per
cage, 7 cages per group). After mating (see above), all mice were
infected with 105 Nc-Spain7 tachyzoites suspended in 100 µl
medium by subcutaneous neck injection. Following infection and
for the duration of the entire experiment, mice were inspected
daily for clinical signs (ruﬄed coat, apathy, hind limb paralysis)
and categorized according to a score sheet approved by the local
authorities.
The ELQ-334 treatment group received ELQ-334 formulated
in corn oil at 10 mg/kg body weight/day for 5 days starting at
day 9 of pregnancy in 100 µl inoculation volume administered
by gavage. Mice from the placebo group received 100 µl
corn oil only. On day 18 post-mating, pregnant females were
separated into individual cages and they gave birth on days
20–22. Subsequently they were allowed to rear their pups for
30 days. Live and stillborn pups were counted, and dead pups
were removed. Non-pregnant mice, dams and their offspring
were evaluated for clinical signs of disease twice a day from the
day of birth to day 30 p.p. Data on the number of dams, non-
pregnant mice, and stillborn pups and those dying postnatally
were monitored. Non-pregnant mice were euthanzed on day 21
p.i., dams and surviving pups were euthanized on day 30 post-
partum. Blood was collected by heart puncture, centrifuged and
serum was stored at −20◦C. Brain and lung tissue were collected
and also stored at−20◦C prior to further processing.
Analysis of Biological Samples
To quantify the parasite load in brains, DNA extraction
was performed according to NucleoSpin R© DNA RapidLyse
protocol (Macherey-Nagel) employing the standard protocol
suitable for animal tissues. The DNA concentrations in all
samples were determined using the QuantiFluor dsDNA system
(Promega, Madison, WI, USA) according to the manufacturer’s
instructions and adjusted to 5 ng/µl with sterile DNase-free
water. Quantification of parasite loads in the brains of non-
pregnant mice and dams was done as described previously (36).
Parasite loads in the brain for N. caninum were assessed as
described previously (25, 28, 37, 38).
Statistics
Fifty percent inhibitory concentrations (IC50s) were calculated
after the logit-log transformation of the relative growth (RG;
control = 1) according to the formula ln(RG/[1-RG]) = a ×
ln(drug concentration)+ b and subsequent regression analysis by
the corresponding software tool contained in the Excel software
package (Microsoft, Seattle, WA, USA). Statistical analysis of the
parasite burdens in brains was done using the Kruskal-Wallis
test. Comparison of positive and negative animals was performed
using the chi-square test. All analyses were performed using the
software package R (39).
RESULTS
In vitro Screening of ELQ Analogs Against
Transgenic N. caninum Tachyzoites
(Ncβ-Gal) Identifies Numerous Highly
Active Compounds
In order to study the effects of the 14 ELQ analogs against
N. caninum tachyzoite proliferation, HFF were exposed to
different concentrations (0–200 nM) of these drugs added
concomitantly with infection by Nc-βGal tachyzoites. Since
DMSO concentrations above 0.5% induced cytotoxicity in HFF
monolayers (data not shown), the maximum ELQ concentration
applied to the cultures was 200 nM. The IC50 values of the ELQ
analogs are shown inTable 1. The lowest IC50 was noted for ELQ-
136 (0.022 nM), but several other compounds exhibited values
below 1 nM, such as endochin, ELQ-121, ELQ-300, ELQ-316,
and ELQ-437. IC50 values between 1 and 5 nM were noted for
ELQ-127, ELQ-271, ELQ-334, ELQ-433, ELQ-434, ELQ-435, and
ELQ-436. One compound, ELQ-432, had a higher IC50 value
(22.5 nM). Since ELQ-316 had been reported earlier to exhibit
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FIGURE 1 | Relative growth curves of Nc-βgal and Nc-Spain7 tachyzoites in response to ELQ-316 and ELQ-334 treatments in vitro. Quantification of Nc-β-Gal
proliferation was carried out by measuring β-galactosidase activity, the proliferation of Nc-Spain7 was assessed by quantitative real time PCR.
outstanding efficacy against T. gondii tachyzoites and tissue cysts
in vivo (16), this compound and its prodrug, ELQ-334 (24)
were selected for further investigations. The respective inhibition
curves for these two compounds are shown in Figure 1.
Since our standardized in vivo model for studies on
N. caninum infection in mice is based on the virulent Nc-
Spain 7 isolate [(25, 40, 41)], the in vitro inhibition achieved
with ELQ-316 and ELQ-334 was also assessed in HFF infected
with Nc-Spain7 tachyzoites, and quantified by real time PCR
(Figure 1). Calculation of the IC50 values for ELQ-316 in
NcSpain7 (IC50 = 0.69 nM) closely matched the respective value
obtained by using the Ncβ-Gal strain (IC50 = 0.66 nM, see
Table 1), and similar values for both Neospora strains were
also obtained for ELQ-334 (Nc-Spain7 IC50 = 1.7 nM; Ncβ-Gal
IC50 = 3.3 nM). Thus, the two N. caninum strains exhibit very
similar susceptibility toward these two ELQs (Figure 1).
TEM Identified Distortion of the
Mitochondrial Matrix, Inner Membrane and
Cristae in N. caninum Tachyzoites as the
Main Ultrastructural Alterations Induced by
ELQ-316 and ELQ-334
TEM was carried out on N. caninum infected HFF exposed
to 1µM ELQ-334 and ELQ-316 at different time-points of
treatments ranging from 6 to 72 h. As shown in Figure 2,
tachyzoites cultured in the absence of any drugs exhibited the
typical features reminiscent for all apicomplexans. Inside their
host cell, they were located within a parasitophorous vacuole
(PV), surrounded by a parasitophorous vacuole membrane
(PVM), and the apical complex containing the conoid,
micronemes, rhoptries, and dense granules were clearly visible
in longitudinal sections (Figures 2A,B). N. caninum tachyzoites
contain a single mitochondrion with a tubular structure, of
which different parts can be seen in a single section. These
mitochondria typically exhibit an electron dense matrix and
numerous cristae, clearly discernible by TEM (Figures 2A–D).
Upon treatment with 1µMELQ-334 (Figure 3) slight alterations
in the matrix of the mitochondrion were visible already
after 6–24 h (Figures 3A–C). The mitochondrial matrix became
less electron dense, primarily in more central areas of the
mitochondrion, and alterations in the cristae structure also
become evident in some parasites (Figures 3A–C). However,
parasites were still proliferating, as evidenced by tachyzoites
undergoing endodyogeny (Figure 3C). After 48 h of ELQ-
334 treatment (Figures 3D,E), the ultrastructural alterations
in the mitochondrial matrix and the cristae became more
evident. In some parasites, membrane stacks formed within the
interior of the mitochondrion. Similar results were obtained
for ELQ-316-treated parasites (Figure 4), although already at
6 h after initiation of treatment, rather massive changes in
the mitochondrial matrix could be visualized (Figure 4A),
which were also increasingly evident after 24 h (Figure 4B) and
48 h (Figures 4C,D). However, no other structural distortions
could be seen in ELQ-334 and ELQ-316 treated tachyzoites.
Most notably, the cytoplasmic organization including rhoptries,
micronemes and dense granules, remained intact, intracellular
parasites appeared to be enclosed in a PV, and other organelles
did not seem to be affected to any large extent. Overall, this
suggests that ELQs do not induce rapid death of N. caninum
tachyzoites, but mainly impact on tachyzoite proliferation in
vitro by primarily acting on the structural integrity of the
mitochondrion.
Long Term Treatment Assays Show That
ELQ-316 and ELQ-334 do not Kill Parasites
Rapidly
HFF infected with Nc-Spain7 tachyzoites, and subsequently
underwent continuous treatment with 500 nM ELQ-316 and
ELQ-334 for extended periods of time, ranging from 3 to 17
days, after which drug pressure was released and cultures were
further maintained without compound. Daily inspection by light
microscopy showed that in control cultures devoid of drugs
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FIGURE 2 | TEM of Nc-Spain 7 tachyzoites cultured in HFF. (A,B) Show a single tachyzoites situated within a parasitophorous vacuole, (C,D) shows a vacuole
containing several parasites undergoing proliferation. The areas framed in (B,D) are shown at higher magnification in (A,C), respectively. Note the mitochondrium
(mito) with a distinct electron dense matrix and cristae; con, conoid; dg, dense granule; rho, rhoptries; arrows point toward the parasitophorous vacuole membrane.
Bar in (A) = 0.46µm; (B) = 2.3µm; (C) = 0.54µm; (D) = 2.3µm.
parasites proliferated rapidly, which would lead to host cell lysis
and re-infection of neighboring cells latest after 3–4 days post-
infection. In contrast, continuous ELQ-treatment for 17 days
resulted in strongly impaired proliferation and a delay of host cell
lysis, but did not act parasiticidal. Lysis plaques could be observed
latest days after removal of the drug (data not shown).
The inherent capacity of N. caninum tachyzoites to undergo
proliferation even in the presence of high concentrations of ELQ-
316 and ELQ-334 was further assessed by immunofluorescence
microscopy employing antibodies directed against NcSAG1 and
IMC1. In untreated HFF (Figure 5A) large parasitophorous
vacuoles containing numerous tachyzoites were present already
after 2 days, closely followed by egress of tachyzoites and
subsequent re-infection of neighboring cells. In samples treated
with ELQ-316, proliferation of parasites was clearly delayed,
and egress was not, or only sporadically, observed (Figure 5B).
Similar results were noted for cultures treated with ELQ-334
(data not shown).
Treatment of pregnant mice with ELQ-334 has no adverse
effects on pregnancy and confers partial inhibition of vertical
transmission of N. caninum.
In vivo studies in mice were carried out with ELQ-334, which
after application in mice is rapidly metabolized to ELQ-316. Due
to the increased absorption of ELQ-334 compared to ELQ-316,
this leads to approximately six times increased exposure (24).
In a first experiment, we investigated whether ELQ-334 would
have an effect on fertility and pregnancy outcome. Results are
summarized in Table 2. Daily treatment of pregnant mice (n= 6
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FIGURE 3 | TEM of Nc-Spain7 tachyzoites cultured in HFF and treated with ELQ-334 for 6 h (A,B), 24 h (C) and 72 h (D,E). A shows numerous tachyzoites in a
parasitophorous vacuole, the framed area is shown at higher magnification in (B). Mitochondria (mito) exhibit slight alterations in some, but not all parasites. Similar
situation after 24 h, in some instances parasites forming daughter zoites (dzo) through endodyogeny can be seen. More pronounced alterations in the mitochondrial
matrix are seen after 72 h (D,E). Rhoptries (rho), dense granules (dg) and micronemes (mic) do not appear to be affected. Bar in (A) = 1.6µm; (B) = 1µm;
(C) = 2µm; (D,E) = 0.8µm.
per group) during days 9–13 of pregnancy with 10 mg/kg/day
during 5 days did not affect fertility, nor did this have a negative
effect on the number of viable pups. Twenty seven pups were
born in the ELQ-334 treatment group and 19 pups in the placebo
group that received corn oil only. A single stillbirth occurred in
the ELQ-334 treated group. No negative impact on the further
development of offspring mice could be detected during 14 days
post-partum, indicating that this compound was safe for use in
pregnant mice.
In the second in vivo study, ELQ-334 treatments were applied
to mice that were experimentally infected with N. caninum
tachyzoites on day 7 of pregnancy (results are summarized in
Table 3). Thus, mice (n = 14 per group) were mated, and during
days 9–13 of pregnancy, they were treated with ELQ-334 or corn
oil as indicated above. Ten mice gave birth to offspring in the
ELQ-334 treated group, 8 in the placebo group, while 4 and 6
mice remained non-pregnant, respectively.
Following infection, none of the adult mice exhibited clinical
signs of neosporosis, with the exception of one dam from the
ELQ-334 treated group on day 45 p.i. This dam had also a high
infection load in the brain. Overall, PCR analysis of brain tissues
of dams and non-pregnant mice at the end of the experiment
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FIGURE 4 | TEM of Nc-Spain7 tachyzoites cultured in HFF and treated with ELQ-316 for 6 h (A), 12 h (B) and 48 h (C,D). The framed area in (D) is shown at higher
magnification in (C). Note that tachyzoites exhibit a dissolved mitochondrial matrix and altered cristae already after 6 h of treatment, and that this aberrant phenotype
remains during subsequent timepoints (white arrows). Bars in (A) = 1µm; (B) = 1.6µm; (C) = 0.8µm.
detected parasite DNA in 7 out of 10 dams and in 3 out of 4
non-pregnant mice that were ELQ-334 treated, while all mice
in the placebo group were PCR positive no matter whether
pregnant or not. Quantification of the cerebral parasite load
in the brain samples of the dams and non-pregnant mice in
the different treatment groups did not reveal any statistically
significant difference between the groups (Figure 6A).
As indicated inTable 3, the 10 dams in the ELQ-334 treatment
group gave birth to 44 pups, the 8 dams in the placebo control
group gave birth to 34 pups. The pup survival curves are shown
in Figure 6B. Seven out of Forty-Four pups (16%) in the ELQ-
334 group died within 2 days post-partum (neonatal mortality).
However, all 37 remaining pups remained healthy without
clinical signs during the 4 weeks follow-up phase. Brain samples
of 19 of these 37 pups (51%) tested PCR positive (Table 3). Of the
34 pups that were born the placebo group, neonatal mortality was
noted for 15 pups (44%), and postnatal mortality occurred for all
but one of the remaining 19 pups (94%). The brain samples of all
pups in the placebo group were PCR-positive.
DISCUSSION
We here report on the in vitro efficacy of 14 distinct ELQ
analogs against the apicomplexan parasite N. caninum in 3-
day proliferation inhibition assays, and also show that two
of these compounds, ELQ-334 and ELQ-316, induce distinct
ultrastructural changes in the parasite mitochondrium. In vitro
culture of N. caninum infected HFF treated with ELQ-334 and
ELQ-316 over extended periods of time indicates that these
compounds slow down, but do not entirely inhibit tachyzoite
proliferation, if treatment is initiated after host cell invasion
has occured. They do not kill these parasites after extended
continuous treatment at 500 nM over 17 days. Nevertheless,
ELQ-334, a prodrug that is metabolized to ELQ-316, exhibits
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FIGURE 5 | Effects of ELQ-316 against already invaded tachyzoites. Nc-Spain7 tachyzoites were allowed to invade HFF during 3 h, then non-invaded parasites were
washed away and cultures were further maintained either in the absence of compounds (control), or 1µM ELQ-316. Samples were fixed and processed for IF after
different timepoints of drug treatment. Specimens were labeled with anti-IMC1 (green) or anti-SAG1 (red). Note that the proliferation inhibitory effects are not very
pronounced when treatment is started after host cell invasion.
promising safety and efficacy in the pregnant mouse model for
N. caninum infection by profoundly increasing pup survival
and inhibiting vertical transmission by almost 50% at 10
mg/kg.
ELQs have been demonstrated to be efficacious against various
protozoan parasites [reviewed in Alday and Doggett (42)].
Like other quinolones, ELQs affect the mitochondrial electron
transport chain. The cytochrome bc1 complex is composed
of cytochrome b, cytochrome c1 and the iron-sulfur protein
(ISP), which form the central core for electron (and associated
proton) transfer. Based on their site of action, inhibitors of
the mitochondrial respiratory chain cytochrome bc1 complex
are classified as either Qo or Qi site inhibitors. The Qo site
oxidizes ubiquinol and the Qi site reduces ubiquinone. Important
currently marketed Qo site inhibitors are atovaquone and
buparvaquone. Atovaquone is used as an alternative treatment
and prophylactic for toxoplasmosis, and in combination with
other drugs for the treatment of malaria and mild to moderate
babesiosis (43). Buparvaquone is the only availabe drug for the
treatment of Theileria parva and T. annulata infection in cattle
(44). Buparvaquone was shown to exhibit promising in vitro
activity and in vivo efficacy in pregnant mice infected with both,
T. gondii (45) and N. caninum (26). Qi site inhibitors, such
as ELQ-316 and other 4(1H)-quinolone-3-diarylethers are not
yet in clinical use, but analogs that do not inhibit mamalian
cytochrome bc1 could potentially be useful for treatment in
species such as cattle and dogs. Recently ELQ-400 was identified
by screening of the MMV (medicines for malaria venture)
Pathogen Box as a highly active compound against N. caninum
tachyzoites in vitro, and ELQ-400 also conferred protection
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TABLE 2 | Treatment with ELQ-334 does not have significant interference in
pregnant BALB/c mice.
Treatment Fertility Pups per dam Mortality
Vehicle (corn oil) 4/6 19/4 0/19
ELQ-334 4/6 27/4 1/27
The number of dams in both experimental groups was equal, and the number of pups in
the ELQ-334 treated group was higher than in the vehicle treated group. In the ELQ-334
treated group one pup died in the pre-natal period.
TABLE 3 | Effects of ELQ-334 treatments on clinical signs, mortality, fertility, and
cerebral Nc-Spain7 infection in non-pregnant mice, dams, and pups.
ELQ-334a Placeboa
NON-PREGNANT FEMALES
Total no. 4 6
Clinical signs 0/4 0/6
Mortality 0/4 0/6
N. caninum PCR positive 3/4 6/6
DAMS
Total no. 10 8
Clinical signs 1/10 0/8
N. caninum PCR positive dams 7/10b 8/8
PUPS
Litter size 44 34
Neonatal mortalitye 7/44c 15/34
Postnatal mortalityf 0/37d 18/19
N. caninum PCR positive pups 19/37d 1/1
a Mice were treated with ELQ-334 in corn oil or with corn oil alone as a placebo control,
infected with Nc-Spain7, and sacrified as described. Adults and surviving pups were
tested for the presence of N. caninum in their brains quantitative real-time PCR. Pups
that had died before the end of the experiment were considered N. caninum positive.
Respective numbers of animals in control and ELQ-334-treated groups were compared
by chi-square tests. bP > 0.1. cP < 0.025. dP < 0.001. eProportion of pups born dead
or that died within the 2 first days post partum. fProportion of pups that died during day
3–28 post partum.
against cerebral infection and disease in a neosporosis cerebral
infection mouse model (36).
The previously reported IC50 values for ELQ-316 and ELQ-
271 against T. gondii were 0.35 and 5.6 nM, respectively (20).
In our assays, the respective values for N. caninum Nc-βGal
were 0.66 and 2.7 nM. While the initial screening was performed
using Nc-βGal, all other studies including mouse experiments
were carried out employing a more virulent strain, Nc-Spain7
(40). The IC50 values for Nc-Spain7 (0.69 nM for ELQ-316 and
1.72 nM for ELQ-334) and Nc-βGal (0.66 nM for ELQ-316 and
3.33 nM for ELQ-334) are in the same range, which confirms
their efficacy and excludes the possibility that these two strains
could differ in susceptibility.
Six of the Fourteen ELQs tested in this study, including ELQ-
316, exhibited IC50s below 1 nM, which represent the lowest
values for drug-induced inhibition reported for N. caninum so
far. The most potent compounds have a fluorine at position 5
on the quinolone core, a structural determinant that is associated
with binding at the Qo site (20). This finding is consistent with
previous ELQ SAR found inT. gondii.Overall, the in vitro efficacy
against N. caninum was similar to T. gondii with the exception
of ELQ-300, which was 75-fold more potent against N. caninum
than T. gondii. The reason for this difference in activity is not
clear as the cytochrome b of the two organisms are more than
99% identical. This result raises the possibility that ELQ-300 may
have an alternate target in N. caninum.
However, it is important to note that a low IC50 value
observed in vitro does not necessarily translate into promising
in vivo efficacy, since many other aspects of a compound such
as absorption, metabolic stability, pharmacokinetic properties,
bioavailability, and other parameters play major roles. The most
potent compounds identified in these studies have poor oral
bioavailability and may be improved by prodrug formulation in
a manner similar to ELQ-316 and ELQ-300. Buparvaquone has a
reported IC50 of 4.9 nM and previous studies have shown greater
efficacy in inhibiting vertical transmission inN. caninum infected
mice than this study of ELQ-334; however, the dose of ELQ-
334 was administered at 10 mg/kg in this study compared to
the 50 mg/kg dose of buparvaquone (26). Similar to ELQ-334,
buparvaquone did not impact significantly on cerebral infection
in dams. The bumped kinase inhibitor BKI-1294 with a markedly
higher IC50 of 40 nM (46) exerted excellent efficacy inN. caninum
infected mice, massively reduced cerebral infection both in dams
and non-pregnant mice, and inhibited vertical transmission to
pups by over 90% when given at 50 mg/kg/d for 8 days (25, 46).
Artemisone, an artemisinin derivative with enhanced efficacy
against malaria displayed an IC50 of 20 nM in vitro, but was
completely ineffective against N. caninum infection in the mouse
model (26). More recently, novel aza-artemisinins have been
synthesized and tested against N. caninum in vitro, displaying
selective toxicity and IC50s of 40 and 110 nM, but they have not
yet been assessed in vivo yet (47).
As visualized by TEM, ELQ-316 and ELQ-334 had a profound
impact on the ultrastructure of the parasite mitochondrion,
which already after a short treatment duration (6 h in the case
of ELQ-316 and 12–24 h for ELQ-334) lost its characteristic
electron densematrix and cristae, both of which are important for
the energy production and synthesis of intermediate metabolites
such as pyrimidine. The delayed effect of ELQ-334 could
be related to its metabolism to ELQ-316 by cell esterases.
There seems to be a marked difference to buparvaquone,
where ultrastructural changes upon treatment with 1µM
buparvaquone were visible only after 3 days of treatment (36).
Thus, these ELQs exert their activity on the mitochondria at
a much earlier time point. As a consequence, proliferation is
delayed in the presence of these two drugs, but obviously not
entirely inhibited. Clearly, these structural alterations do not
automatically imply that all mitochondrial activities are impaired,
thus the question how these parasites can overcome this obvious
structural defect needs to be addressed in further studies. ELQs
block oxidative phosphorylation, thereby causing the relocation
of electrons to other biomolecules generating free radicals and
reactive oxygen species (ROS) detrimental to the parasite. By the
disappearance of structurally intact mitochondria, the parasite
could overcome this effect of the drugs, thus energy metabolism
is then dependent on glycolysis, and intermediate metabolites
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FIGURE 6 | (A). Cerebral parasite load in non-pregnant mice and dams as determined by quantitative real time PCR of brain samples of ELQ-334 treated and
placebo-treated control mice. Values are given as number of tachyzoites per µg DNA. There are no significant differences. (B). Kaplan-meier survival curves of pups
born from ELQ-334 treated dams and placebo-treated control mice infected with N. caninum tachyzoites.
need to be scavenged from the host, which in turn would ensure
survival, despite impaired proliferation. Similar findings were
recently obtained in buparvaquone treated Besnoitia besnoiti
tachyzoites grown in human fibroblasts, which were found to
rapidly adapt to buparvaquone concentrations that were 5,000
times higher than the original IC50 (48). TEM also identified
a distinct PV and PVM in HFF infected with both, non-
treated and drug-treated N. caninum tachyzoites, and since the
compounds are added concomitantly with the parasites, we
conclude that the processes leading to host cell invasion and
PV formation were not notably inhibited by these compounds.
This is in contrast to ELQ-400, which was identified through
in vitro screening of the MMV Pathogen Box (30). ELQ-400
had a notably higher IC50 (4 nM), but was shown to impact on
both, host cell invasion and intracellular proliferation, and the
most striking feature that could be observed by TEM was also
the dramatic breakdown of the mitochondria (41). In contrast,
as suggested by immunofluorescence studies and initiating
treatments only after parasites have invaded their host cells, ELQ-
316 and ELQ-334 act mainly on host cell invasion rather than
intracellular proliferation. ELQ-400 has not yet been evaluated
in the pregnant neosporosis mouse model, but was shown
to negatively impact on cereberal infection in non-pregnant
Balb/c mice, being more efficient than ELQ-334 in preventing
cerebral infection (30). The higher efficacy of ELQ-400 could
be explained by a recent study suggesting that ELQ-400 targets
both Qo and Qi sites on cytochrome b (19) or may be related to
pharmacokinetics.
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The result for ELQ-334 in the pregnant mouse model are
promising. Under the conditions used, the compound was
safe and did not interfere in pregnancy outcome, and there
are no issues that would indicate toxicity. ELQ-334 treatment
in N. caninum infected mice reduced loss of offspring by
partially inhibiting neonatal mortality and completely preventing
postnatal mortality. In addition, vertical transmission was
prevented in approximately 50% of the surviving pups. A
compound that blocks vertical transmission completely has
not been identified to date, but other drugs with similar or
even better efficacy haven been reported, such as toltrazuril,
BKIs and buparvaquone [(25, 41, 46, 49, 50)]. In this
respect, ELQ-334 could be potentially combined with another
quinolone such as the Qo site inhibitors atovaquone (51) or
buparvaquone, to achieve dual site inhibition and probably
increased efficacy, or with another compound of different
mode of action. Proof of concept for such a combination
therapy was provided in immunodeficient mice experimentally
infected with B. microti, where radical cure was achieved
using a combination of ELQ-334 and atovaquone at a
dosage of 5 mg/kg, with no recrudescence of babesiosis
during a time span of 122 after discontinuation of therapy
(24). Future investigations should focus on such combination
approaches.
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